Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ).
IRLAB Therapeutics reported that the first patients with Parkinson’s disease and apathy have been dosed in the LIFT-PD clinical study evaluating its drug candidate IRL757, triggering a milestone payment of USD 3 million that helped lift net sales to SEK 39.4 million and turn operating profit positive for the quarter. The company also highlighted that results from its REACT-PD study were well received at a major international AD/PD conference, proposed new board appointments ahead of the AGM, and strengthened its balance sheet through a rights issue and overallotment totaling about SEK 102 million, bolstering its financial position for ongoing clinical development despite a lower share price and reduced cash compared with a year earlier.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish biopharmaceutical company focused on developing novel treatments for Parkinson’s disease and related neurological disorders. The company’s pipeline includes drug candidates such as IRL757 and IRL942, targeting symptoms like apathy and cognitive impairment to improve quality of life for patients in these underserved areas.
Average Trading Volume: 218,344
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK119.6M
For an in-depth examination of IRLAB.A stock, go to TipRanks’ Overview page.